| INTRODUCTION
Chronic hepatitis C is the leading cause of cirrhosis, hepatocellular carcinoma, and death from liver diseases; it is also one of the leading indications for liver transplantation in the USA. 1 The availability of all-oral direct-acting antivirals (DAAs) has dramatically changed the hepatitis C virus (HCV) treatment landscape. These therapies are highly effective-results from clinical trials as well as those from real-world studies have shown sustained virologic response (SVR)
rates of 90%-100% with the new DAAs. 2 In addition, an increasing number of patients are eligible for therapy due to the absence of interferon and ribavirin in these new therapy regimens.
Oral DAAs offer an opportunity to eliminate HCV infection as a public health problem. The United States' National Academies of Science, Engineering, and Medicine recently set targets for HCV elimination, which includes treating 80% of all eligible persons with chronic HCV by 2030. Despite the high SVR rates achievable with oral DAA regimens, a small percentage of patients fail to achieve SVR due to virological failure. Timely treatment of this population is required to prevent long-term sequelae of HCV in these patients and to aid in reaching the elimination targets.
Currently recommended first-line antiviral therapies in the USA include all-oral DAA regimens containing a nonstructural protein 5A (NS5A) inhibitor or non-NS5A inhibitor. 3 Among patients who have failed NS5A inhibitors, previous retreatment options were limited and emerging resistance was an important consideration for retreatment selection. The AASLD-IDSA guidance recently revised their recommendation for re-treatment of patients with recently available DAAs in whom previous treatment with any HCV NS5A or non-NS5A inhibitors had failed. 3 Because the costs of new DAAs are different from available DAAs, understanding the number of people who require re-treatment or will fail to achieve SVR even after multiple treatments is important for budget impact and disease burden projections, especially for payers.
The total number of treatment failures at the population level depends on several factors such as the number of patients newly diagnosed with HCV, current treatment penetration rates, treatment access restrictions by fibrosis stage or other factors, 4 and market share of NS5A vs non-NS5A inhibitors. Our objective was to project the number of patients infected with HCV who will fail currently approved oral DAA therapies (including NS5A vs non-NS5A inhibitor-containing regimens) and will require re-treatment.
2 | ME TH ODS
| Model overview
We used a previously developed mathematical disease model, Hepatitis C Disease Burden Simulation model (HEP-SIM), to simulate the changing HCV environment and predict number of HCV patients needing re-treatment. 5, 6 The HEP-SIM model simulates the current clinical management of HCV including the implementation of birth- 9 and a large multicentre follow-up study of patients with advanced fibrosis. 10 We projected the number of patients undergoing treatment between 2014 and 2020; and the number of patients who failed
DAAs including both NS5A and non-NS5A inhibitors. Below we describe the key components of HEP-SIM; further details can be found elsewhere.
5,6
| Patient demographics
The base-case population in HEP-SIM represented HCV-infected patients in the USA. We defined the age distributions and sex based on the NHANES data, and defined HCV genotype, stage of liver disease, and prior HCV treatment history based on published studies (Table S1 ). An updated HCV incidence was defined based on the recently reported data by the CDC (Table S2 ). (Table S3) . 11 We estimated disease progression in cirrhosis and decompensated cirrhosis from published observational studies. 12, 13 Patients who developed decompensated cirrhosis or hepatocellular carcinoma were eligible to receive a liver transplant [14] [15] [16] and had higher mortality rates. in CDC guidelines on HCV screening. 18 We assumed that 90% of the patients covered by healthcare insurance and 10% of those who were uninsured were offered HCV testing. 19 Similar to the assumptions made by the CDC's study to evaluate birth-cohort HCV screening, we assumed that among those who were offered testing, 91%
| Natural history of HCV
would accept it, and 90% of those who tested positive would receive those results. 19 We assigned the uptake of screening such that the majority of these patients would receive screening gradually over 7 years beginning in 2013. In addition to birth-cohort screening, we implemented HCV diagnosis through usual care, which also included risk-based screening (Tables S4-S6 ). GET studies (Table S7 ).
| Treatment waves

| Treatment uptake and prioritisation
We used published studies and drug sales as a surrogate to estimate the number of patients receiving treatment in a given year (Table S8 ). In 2014, approximately 150 000 patients initiated DAA treatment. 20 In 2015 and 2016, 280 000 initiated treatment based on reported drug sales. 21 From 2017 onwards, we assumed that the maximum annual treatment capacity would not exceed 280 000 and the actual number of patients receiving treatment was dependent on patients' awareness status, prior treatment history, and insurance status. We used commercial claims data from QuintilesIMS and IPSOS to estimate the market share of NS5A vs non-NS5A inhibitorcontaining regimens by HCV genotype (Table S9) . 
| Model outcomes
We projected the number of patients who failed to achieve SVR in the era of DAAs from 2014 to 2020. We presented these outcomes 
ing trend in HCV incidence rate from 2016 onwards (Table S10) , (2) higher treatment uptake rate of 500 000 patients per year from 2018 onwards, (3) changes in the market share of NS5A vs non-NS5A inhibitors from 2017 onwards, (4) scaling-up birth-cohort screening by 25% (relative to the base case), and (5) scaling-down birth-cohort screening by 25% (relative to the base case).
3 | RESULTS Figure 2A shows the number of patients alive who either are virae- would drop to 61 000 in spite of the fact that around 844 000 patients would still be viraemic in that year.
Next, we projected the number of patients who would fail to achieve SVR in the era of DAAs. Figure 4A shows the number of patients living with HCV after failing to achieve SVR after treatment 
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Outcomes of the scenario analyses showed that results were not sensitive to the rising HCV incidence trends or change in the uptake of HCV screening. However, compared with the base case, the number of people who failed to achieve SVR (NS5A or non-NS5A inhibitors) changed by more than 10% when the treatment capacity was increased to 500 000 per year or when the market share of NS5A inhibitors was changed to 90% (Table S11 ). In addition, the number of alive patients in a given year who failed at least one treatment were also sensitive to the treatment capacity (Table S12) , and the number of people aware of their HCV infection (in year 2018) were sensitive to the treatment capacity (Table S13 ).
| DISCUSSION
The availability of well-tolerated and highly effective DAAs offers a new hope to eliminate HCV as a public health threat. However, even with the newer generations of DAAs, a small proportion of patients will fail to achieve SVR and could develop advanced sequelae such as decompensated cirrhosis and HCC. In this study, we simulated the current clinical landscape of HCV treatment and projected the number of patients in the USA who would receive treatment, achieve SVR, or require re-treatment. We found that in the era of DAAs, a total of 1.50 million people would receive treatment between 2014 and 2020 and around 124 000 (8.3%) would fail to achieve SVR; the majority of those who fail treatment would have been exposed to NS5A inhibitors. Timely and effective retreatment of these patients could prevent the long-term sequelae of HCV.
Earlier studies have estimated the number of patients who would remain viraemic in the era of DAAs, 6 and projected disease burden under different screening and treatment scenarios. 5, 6, 25, 26 This study adds new information by estimating the number of patients who would fail to achieve SVR, especially with NS5A inhibitors, and require retreatment in the era of DAAs. Providing this data allows payers to assess the budget impact of HCV treatment and disease burden projections. Although the DAAs have been shown to be cost-effective/saving, 27,28 budget needed to treat all HCV patients remains challenging in some settings. 29 We observed that under current clinical practice, the number of Our study also shows a growing population of patients alive following HCV cure. As this patient population increases, disease management efforts focused on regular surveillance of persons with pretreatment advanced fibrosis or cirrhosis is important, as they remain at risk of developing hepatocellular carcinoma. 31 In addition, the burden of management for these patients may also shift from specialists to general practitioners. If this transition does take place, future efforts should also focus on increasing the awareness among general practitioners and internists regarding appropriate medical care for patients cured of HCV.
This modelling-based study has some limitations. First, the analysis only included non-institutionalised HCV-infected persons as estimated by the NHANES studies. Therefore, our results likely underestimated the number of viraemic patients. Secondly, recent data suggest that the uptake of birth-cohort screening in practice remains low, therefore, our model may have over-estimated the number of patients who would become aware of their HCV status. Thirdly, we did not include in the model HIV-HCV co-infection, which is beyond the scope of the current work. Fourth, we did not consider the possibility of regression of fibrosis after SVR, which is unlikely to effect the results presented in this study. Finally, we made assumptions about future treatment capacity, which could vary over time.
In conclusion, we found that even in the era of highly effective DAAs, there are still going to be challenges. To achieve HCV elimination a national strategy will need to support the development of systems aimed at increasing the diagnosis of HCV and plans outlining the effective and timely retreatment of patients who have failed on DAAs. 
